$43.79
6.52% yesterday
Nasdaq, Nov 25, 09:49 pm CET
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Moderna Stock price

$43.66
-9.43 17.76% 1M
-122.95 73.80% 6M
-55.79 56.10% YTD
-34.06 43.82% 1Y
-229.73 84.03% 3Y
+23.66 118.30% 5Y
+25.06 134.73% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+2.55 6.20%
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Key metrics

Market capitalization $16.80b
Enterprise Value $11.29b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.23
P/S ratio (TTM) P/S ratio 3.31
P/B ratio (TTM) P/B ratio 1.41
Revenue growth (TTM) Revenue growth -44.06%
Revenue (TTM) Revenue $5.07b
EBIT (operating result TTM) EBIT $-2.70b
Free Cash Flow (TTM) Free Cash Flow $-3.96b
Cash position $6.87b
EPS (TTM) EPS $-5.82
P/E forward negative
P/S forward 5.14
EV/Sales forward 3.45
Short interest 11.75%
Show more

Create a Free Account to create an Moderna alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Moderna Stock Analysis

Analyst Opinions

28 Analysts have issued a Moderna forecast:

11x Buy
39%
14x Hold
50%
3x Sell
11%

Analyst Opinions

28 Analysts have issued a Moderna forecast:

Buy
39%
Hold
50%
Sell
11%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
5,073 5,073
44% 44%
100%
- Direct Costs 1,985 1,985
68% 68%
39%
3,088 3,088
7% 7%
61%
- Selling and Administrative Expenses 962 962
1% 1%
19%
- Research and Development Expense 4,496 4,496
8% 8%
89%
-2,370 -2,370
7% 7%
-47%
- Depreciation and Amortization 331 331
33% 33%
7%
EBIT (Operating Income) EBIT -2,701 -2,701
1% 1%
-53%
Net Profit -2,224 -2,224
36% 36%
-44%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Positive
Seeking Alpha
about 4 hours ago
Moderna's stock is undervalued, so I maintain a positive outlook with a $97 price target for next year. 3Q24 results show good COVID-19 revenue, cost efficiency, and a significant cash balance, but RSV vaccine sales underperformed. The pipeline includes promising next-gen COVID-19, RSV, flu, CMV, norovirus, and oncology drugs, with substantial revenue potential by 2027.
Neutral
Accesswire
one day ago
CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: 7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ET Piper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ET A live webcast of each of these presentations will be availab...
Positive
Investopedia
4 days ago
Moderna (MRNA) shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about the vaccine maker's pipeline and cash position.
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,600
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today